Brokerages expect Eli Lilly and Co (NYSE:LLY) to post sales of $5.47 billion for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Eli Lilly and’s earnings. The highest sales estimate is $5.53 billion and the lowest is $5.42 billion. Eli Lilly and posted sales of $5.23 billion in the same quarter last year, which suggests a positive year-over-year growth rate of 4.6%. The business is expected to announce its next quarterly earnings report on Tuesday, April 24th.

On average, analysts expect that Eli Lilly and will report full year sales of $5.47 billion for the current year, with estimates ranging from $23.05 billion to $23.67 billion. For the next fiscal year, analysts forecast that the business will post sales of $23.89 billion per share, with estimates ranging from $23.30 billion to $24.36 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Eli Lilly and.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The business had revenue of $6.16 billion during the quarter, compared to analysts’ expectations of $5.93 billion. During the same period in the previous year, the business posted $0.95 EPS. The business’s quarterly revenue was up 7.0% compared to the same quarter last year.

Several analysts have commented on the stock. Leerink Swann lifted their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, October 24th. Goldman Sachs Group cut shares of Eli Lilly and from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $86.98 to $95.00 in a research note on Tuesday, January 16th. Jefferies Group set a $100.00 price objective on shares of Eli Lilly and and gave the company a “buy” rating in a research note on Tuesday, January 16th. Finally, Credit Suisse Group reaffirmed a “hold” rating on shares of Eli Lilly and in a report on Wednesday, December 13th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $92.02.

In related news, insider Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $81.09, for a total value of $72,981.00. Following the completion of the sale, the insider now owns 4,130 shares of the company’s stock, valued at approximately $334,901.70. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the sale, the insider now directly owns 123,084,104 shares of the company’s stock, valued at approximately $10,856,017,972.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 259,610 shares of company stock valued at $22,727,406. Insiders own 0.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of LLY. Beach Investment Management LLC. acquired a new stake in Eli Lilly and during the 2nd quarter worth $400,000. Dupont Capital Management Corp boosted its stake in Eli Lilly and by 230.0% during the 2nd quarter. Dupont Capital Management Corp now owns 45,831 shares of the company’s stock worth $3,772,000 after purchasing an additional 31,941 shares during the last quarter. LMR Partners LLP acquired a new stake in Eli Lilly and during the 2nd quarter worth $1,672,000. Dowling & Yahnke LLC boosted its stake in Eli Lilly and by 0.9% during the 2nd quarter. Dowling & Yahnke LLC now owns 61,575 shares of the company’s stock worth $5,068,000 after purchasing an additional 544 shares during the last quarter. Finally, State of Wisconsin Investment Board boosted its stake in Eli Lilly and by 16.5% during the 2nd quarter. State of Wisconsin Investment Board now owns 1,046,784 shares of the company’s stock worth $86,150,000 after purchasing an additional 148,360 shares during the last quarter. 76.45% of the stock is owned by institutional investors.

Shares of Eli Lilly and (NYSE LLY) traded up $2.02 during midday trading on Wednesday, reaching $76.23. 8,940,000 shares of the company’s stock traded hands, compared to its average volume of 4,970,000. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and has a twelve month low of $73.69 and a twelve month high of $89.09. The firm has a market cap of $86,220.00, a PE ratio of -381.15, a price-to-earnings-growth ratio of 1.36 and a beta of 0.23.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a dividend yield of 2.95%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s payout ratio is -1,040.00%.

COPYRIGHT VIOLATION WARNING: This story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://theolympiareport.com/2018/02/10/analysts-anticipate-eli-lilly-and-co-lly-will-post-quarterly-sales-of-5-47-billion.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.